Statin treatment in routine clinical practice: Insights from the STATRIP physician survey

IF 3.4 Q3 PERIPHERAL VASCULAR DISEASE

Atherosclerosis plus Pub Date : 2026-03-01 Epub Date: 2026-01-17 DOI:10.1016/j.athplu.2026.01.003

Panagiota Anyfanti , Christina Antza , Dimitrios Poulis , Konstantinos Konstantaros , Makrina Savvoulidou , Georgios Styliadis , Vasilios Kotsis

{"title":"Statin treatment in routine clinical practice: Insights from the STATRIP physician survey","authors":"Panagiota Anyfanti , Christina Antza , Dimitrios Poulis , Konstantinos Konstantaros , Makrina Savvoulidou , Georgios Styliadis , Vasilios Kotsis","doi":"10.1016/j.athplu.2026.01.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Statins remain to date the primary therapeutic option for dyslipidemia. However, a significant portion of patients with dyslipidemia fail to achieve optimal low-density lipoprotein targets for reasons often related to treating physicians. The aim of STAtin Treatment in Routine clinical Practice (STATRIP) survey was to report and quantify perceptions and common beliefs regarding treatment with statins, among physicians implicated in the primary and secondary care of patients with dyslipidemia.</div></div><div><h3>Methods and results</h3><div>This observational cross-sectional study was conducted using an online-distributed questionnaire, which was designed to cover a wide range of physicians’ knowledge and perceptions on treatment with statins. A total of 261 health care providers filled out the survey, mostly general practitioners and internists (93.5 %). Study participants clearly expressed their concerns regarding statin-related side effects, including fears on interactions with other medication, muscle aches and pain, increase in liver enzymes, and gastrointestinal disorders. Myalgias were observed by physicians in as many as 29.2 % of patients receiving rosuvastatin, and in as many as 26.5 % receiving atorvastatin. Combination lipid-lowering therapy with ezetimibe was reported by only 53.6 % of participants as a prevalent strategy for uncontrolled individuals. Only 58.6 % apply non-HDL cholesterol measurements in their clinical practice.</div></div><div><h3>Conclusions</h3><div>Our study provides a clear perspective of treating physicians regarding statin prescription patterns. Several misconceptions, especially regarding statin-related adverse effects, hold well among treating physicians. Insufficient implementation of dyslipidemia guidelines calls for more targeted educational interventions to achieve optimal management of patients with dyslipidemia.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"63 ","pages":"Pages 28-33"},"PeriodicalIF":3.4000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667089526000039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Statins remain to date the primary therapeutic option for dyslipidemia. However, a significant portion of patients with dyslipidemia fail to achieve optimal low-density lipoprotein targets for reasons often related to treating physicians. The aim of STAtin Treatment in Routine clinical Practice (STATRIP) survey was to report and quantify perceptions and common beliefs regarding treatment with statins, among physicians implicated in the primary and secondary care of patients with dyslipidemia.

Methods and results

This observational cross-sectional study was conducted using an online-distributed questionnaire, which was designed to cover a wide range of physicians’ knowledge and perceptions on treatment with statins. A total of 261 health care providers filled out the survey, mostly general practitioners and internists (93.5 %). Study participants clearly expressed their concerns regarding statin-related side effects, including fears on interactions with other medication, muscle aches and pain, increase in liver enzymes, and gastrointestinal disorders. Myalgias were observed by physicians in as many as 29.2 % of patients receiving rosuvastatin, and in as many as 26.5 % receiving atorvastatin. Combination lipid-lowering therapy with ezetimibe was reported by only 53.6 % of participants as a prevalent strategy for uncontrolled individuals. Only 58.6 % apply non-HDL cholesterol measurements in their clinical practice.

Conclusions

Our study provides a clear perspective of treating physicians regarding statin prescription patterns. Several misconceptions, especially regarding statin-related adverse effects, hold well among treating physicians. Insufficient implementation of dyslipidemia guidelines calls for more targeted educational interventions to achieve optimal management of patients with dyslipidemia.

查看原文本刊更多论文

他汀类药物在常规临床实践中的应用：来自STATRIP医师调查的见解

他汀类药物至今仍是治疗血脂异常的主要选择。然而，由于治疗医生的原因，很大一部分血脂异常患者未能达到最佳低密度脂蛋白目标。他汀类药物在常规临床实践中的治疗（STATRIP）调查的目的是报告和量化参与血脂异常患者初级和二级护理的医生对他汀类药物治疗的看法和共同信念。方法和结果本观察性横断面研究采用在线分发的调查问卷进行，旨在涵盖医生对他汀类药物治疗的广泛知识和看法。共有261名卫生保健提供者填写了调查，其中大多数是全科医生和内科医生（93.5%）。研究参与者明确表达了他们对他汀类药物副作用的担忧，包括担心与其他药物相互作用、肌肉疼痛、肝酶增加和胃肠道疾病。医生在接受瑞舒伐他汀治疗的患者中观察到多达29.2%的患者有肌痛，而接受阿托伐他汀治疗的患者中有26.5%的患者有肌痛。据报道，只有53.6%的参与者将依折替米联合降脂治疗作为不受控制个体的普遍策略。只有58.6%的人在临床实践中使用非高密度脂蛋白胆固醇测量。结论我们的研究为治疗医生提供了关于他汀类药物处方模式的清晰视角。一些误解，特别是关于他汀类药物相关的不良反应，在治疗医生中普遍存在。血脂异常指南实施不足，需要更有针对性的教育干预，以实现对血脂异常患者的最佳管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊